Reaction
Pulmonary Cavitation reporting signals
As of the last recalculation, Pulmonary Cavitation appears in 853 FAERS reports alongside 25 co-occurring drug terms. The strongest observed disproportionality signal is AMIKACIN (PRR 56.8).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Amikacin | 38 | 56.8 | 57.0 |
| Rifampin | 32 | 55.5 | 55.7 |
| Regorafenib | 16 | 34.3 | 34.3 |
| Voriconazole Injection | 29 | 33.7 | 33.7 |
| Remdesivir | 18 | 33.6 | 33.7 |
| Azithromycin | 52 | 33.5 | 33.6 |
| Azithromycin Monohydrate | 52 | 32.4 | 32.4 |
| Sirolimus | 17 | 31.4 | 31.4 |
| Amphotericin B | 14 | 27.7 | 27.7 |
| Voriconazole | 33 | 27.5 | 27.6 |
| Moxifloxacin Hydrochloride | 22 | 27.2 | 27.2 |
| Micafungin Sodium | 9 | 26.2 | 26.2 |
| Itraconazole | 12 | 25.4 | 25.4 |
| Rifampicin | 10 | 24.4 | 24.4 |
| Azithromycin Dihydrate | 51 | 22.5 | 22.5 |
| Daspone | 8 | 20.2 | 20.2 |
| Dapsone Gel, 5% | 8 | 20.2 | 20.2 |
| Clarithromycin | 27 | 19.8 | 19.8 |
| Ganciclovir Sodium | 8 | 18.6 | 18.6 |
| Dapsone | 8 | 18.4 | 18.5 |
| Meropenem | 23 | 17.9 | 18.0 |
| Ceftriaxone | 21 | 16.0 | 16.0 |
| Ceftriaxone Sodium | 22 | 14.3 | 14.3 |
| Lenvatinib | 9 | 6.8 | 6.8 |
| Cabozantinib | 12 | 6.2 | 6.2 |